Humacyte, Inc. Company Profile

01:58 EDT 20th March 2018 | BioPortfolio

Humacyte, Inc., a privately held company founded in 2004, is a medical research, discovery and development company with clinical and pre-clinical stage investigational products. Humacyte is primarily focused on developing and commercializing a proprietary novel technology based on human tissue-based products for key applications in regenerative medicine and vascular surgery. The company uses its innovative, proprietary platform technology to engineer human, extracellular matrix-based tissues that can be shaped into tubes, sheets, or particulate conformations, with properties similar to native tissues. These are being developed for potential use in many specific applications, with the goal to significantly improve treatment outcomes for many patients, including those with vascular disease and those requiring hemodialysis. The company’s proprietary technologies are designed to create off-the-shelf products that, once approved, can be utilized in any patient. The company web site is

News Articles [5 Associated News Articles listed on BioPortfolio]

Funding round pulls in $75M for Humacyte

A round of Series C preferred stock financing brought in $75 million for Morrisville, N.C.-based Humacyte.  -More- 

Humacyte closes $75mm Series C round

Humacyte Inc. (extracellular tissue-based products for regenerative medicine) raised $75mm from existing investors and new buyer PointState Capital through its Series C round. Funding will support con...

Humacyte raises $75M series C

Humacyte completes enrollment in Phase III of Humacyl for ESRD

Humacyte Closes $75 Million Series C Financing

Funding expected to support Humacyte’s ongoing and future clinical trials, including its pivotal Phase III HUMANITY® study and completion of Humacyte’s proprietary bioprocess...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD

This study will evaluate how well Humacyte's Human Acellular Vessel (HAV) works when surgically implanted into a leg to improve blood flow in patients with peripheral arterial disease (PAD...

Humacyte Human Acellular Vessel (HAV) in Patients With Limb-threatening Peripheral Arterial Trauma

This study evaluates the use of the Human Acellular Vessel (HAV) in adults with arterial trauma in the lower limb who are undergoing vascular reconstructive surgery. All subjects will be i...

Companies [1 Associated Companies listed on BioPortfolio]

Humacyte, Inc.

Humacyte, Inc., a privately held company founded in 2004, is a medical research, discovery and development company with clinical and pre-clinical stage investigational products. H...

More Information about "Humacyte, Inc." on BioPortfolio

We have published hundreds of Humacyte, Inc. news stories on BioPortfolio along with dozens of Humacyte, Inc. Clinical Trials and PubMed Articles about Humacyte, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Humacyte, Inc. Companies in our database. You can also find out about relevant Humacyte, Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...

Corporate Database Quicklinks

Searches Linking to this Company Record